Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Therapeutics

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2016.06.005PMID 27368115PMCID PMC4985173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

  2017cited by this paper
• Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA

  2015cited by this paper
• High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules

  2015cited by this paper
• Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.

  2014cited by this paper
• Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.

  2014cited by this paper
• Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.

  2014cited by this paper
• The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

  2014cited by this paper
• Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis

  2014cited by this paper
• Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma

  2013cited by this paper
• A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease.

  2013cited by this paper
• Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification

  2013cited by this paper
• Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.

  2013cited by this paper
• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

  2012cited by this paper
• Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.

  2012cited by this paper
• The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

  2012cited by this paper
• Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients—A single institution retrospective study of 292 lung adenocarcinoma

  2012cited by this paper
• Reduced lung-cancer mortality with low-dose computed tomographic screening.

  2011cited by this paper
• Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).

  2011cited by this paper
• Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Bronchioloalveolar carcinoma

  2010cited by this paper
• Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

  2010cited by this paper
• IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

  2009cited by this paper
• Bronchioloalveolar carcinoma: the case for two diseases.

  2008cited by this paper
• Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

  2008cited by this paper
• Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.

  2007cited by this paper
• Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

  2006cited by this paper
• A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.

  2006cited by this paper
• Identification of bronchioalveolar stem cells in normal lung and lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.

  2005cited by this paper
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

  2005cited by this paper
• EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.

  2005cited by this paper
• Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).

  2004cited by this paper
• Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126).

  2004cited by this paper
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Genetic Profile of Cumulative Mutational Damage Associated With Early Pulmonary Adenocarcinoma: Bronchioloalveolar Carcinoma vs. Stage I Invasive Adenocarcinoma

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival.

  2003cited by this paper
• Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.

  2002cited by this paper
• Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung.

  2001cited by this paper
• Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.

  2001cited by this paper
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

  2001cited by this paper
• Correlation between genetic alterations and histopathological subtypes in bronchiolo‐alveolar carcinoma and atypical adenomatous hyperplasia of the lung

  2000cited by this paper
• Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

  2000cited by this paper
• p53 alterations in atypical alveolar hyperplasia of the human lung.

  1998cited by this paper
• Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease.

  1998cited by this paper
• Bronchioloalveolar carcinoma.

  1996cited by this paper
• K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.

  1996cited by this paper
• The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin.

  1994cited by this paper
• Bronchioloalveolar carcinoma.

  1987cited by this paper

• OTT_A_294953 1093..1099

  2021cites this paper
• Synchronous Multiple Lung Cancers with Lymph Node Metastasis and Different EGFR Mutations: Intrapulmonary Metastasis or Multiple Primary Lung Cancers?

  2021cites this paper
• Molecular Diagnostics in Non-Small Cell Lung Carcinoma

  2020cites this paper
• Whole Exome Sequencing of Simultaneous Primary Multifocal Lung Cancer (SMPLC): Case Report and Bioinformatics Analysis

  2020cites this paper
• Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.

  2019cites this paper
• 多发肺结节的基础研究和临床治疗进展

  2019cites this paper
• Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

  2017cites this paper
• HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

  2017cites this paper
• Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

  2017cites this paper
• Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status

  2017cites this paper
• Cancer Genomics: Targeting Inherited Risk and Somatic Mutations in Precision Oncology.

  2016cites this paper
• Genomics and the Prediction and Characterization of Cancer and Some Observations About Pancreatic Cancer.

  2016cites this paper